This is a working overview of regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-02 and is reviewed periodically as new material appears.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
=== Denaturing high performance liquid chromatography === Denaturing high performance liquid chromatography (DHPLC) uses reversed-phase HPLC to interrogate SNPs. The key to DHPLC is the solid phase which has differential affinity for single and double-stranded DNA. In DHPLC, DNA fragments are denatured by heating and then allowed to reanneal. The melting temperature of the reannealed DNA fragments determines the length of time they are retained in the column. Using PCR, two fragments are generated; target DNA containing the SNP polymorphic site and an allele-specific DNA sequence, referred to as the normal DNA fragment. This normal fragment is identical to the target DNA except potentially at the SNP polymorphic site, which is unknown in the target DNA. The fragments are denatured and then allowed to gradually reanneal. The reannaled products are added to the DHPLC column. If the SNP allele in the target DNA matches the normal DNA fragment, only identical homoduplexes will form during the reannealing step. If the target DNA contains a different SNP allele than the normal DNA fragment, heteroduplexes of the target DNA and normal DNA containing a mismatched polymorphic site will form in addition to homoduplexes. The mismatched heteroduplexes will have a different melting temperature than the homoduplexes and will not be retained in the column as long. This generates a chromatograph pattern that is distinctive from the pattern that would be generated if the target DNA fragment and normal DNA fragments were identical. The eluted DNA is detected by UV absorption.
== Concept == Protein nutrition is complex because any proteinogenic amino acid may be the limiting factor in metabolism. Mixing livestock feeds can optimize for growth, or minimize cost while maintaining adequate growth. Similarly, human nutrition is subject to Liebig's law of the minimum: The lowest level of one of the essential amino acids will be the limiting factor in metabolism.
The draining of the Qurna Marshes was an irrigation project in Iraq during and immediately after the war, to drain a large area of marshes in the Tigris–Euphrates river system. Formerly covering an area of around 3,000 km2 (1,200 sq mi), the large complex of wetlands were nearly emptied of water, and the local Shi'ite population relocated, following the war and 1991 uprisings. By 2000, the United Nations Environment Programme estimated that 90% of the marshlands had disappeared, causing desertification of over 7,500 square miles (19,000 km2). The draining occurred in Iraq and to a smaller degree in Iran between the 1950s and 1990s to clear large areas of the marshes. Formerly covering an area of around 20,000 km2 (7,700 sq mi), the large complex of wetlands was 90% drained before the 2003 Invasion of Iraq. The marshes are typically divided into three main sub-marshes, the Hawizeh, Central, and Hammar Marshes and all three were drained at different times for different reasons. Initial draining of the Central Marshes was intended to reclaim land for agriculture but later all three marshes would become a tool of war and revenge. Many international organizations such as the UN Human Rights Commission, the Islamic Supreme Council of Iraq, the Wetlands International, and Middle East Watch have described the project as a political attempt to force the Marsh Arabs out of the area through water diversion tactics.
=== Predators === General predators like spiders, ants, and lady beetles prey on cabbage looper eggs and larvae, removing 50% of the eggs and 25% of the larvae within three days. Lady beetles consume at the highest rate. Other common predators of cabbage looper larva include Orius tristicolor, Nabis americoferus, and Geocoris pallens.
The tetrahydrofuran ring is found in diverse natural products including lignans, acetogenins, and polyketide natural products. Diverse methodology has been developed for the synthesis of substituted THFs.
Sources: en.wikipedia.org
Narrated by Alun Lewis, directed by Gary Leach, produced by Geoff Deehan, produced by Sandlin Productions 24 November The Dyslexic Engineer, about Ben Bowlby, born on 2 November 1966; his VS91 car at Snetterton Circuit, with a Vauxhall Astra engine, with footage mostly from the end of the earlier documentary in September 1990; his studies at the Polytechnic of East London; Richard Bowlby, his father from Hampstead, who also realised that he was dyslexic; Rosalind Rathouse, his former remedial teacher; Roy Greenfield, a retired maths teacher from King Alfred School, London, who believed that perhaps people would adapt to mathematics more if the subject was taught later in life, as people are often put off the subject at secondary school; Ben gained nine O-levels but couldn't acquire Mathematics A-level above grade E after, two attempts; Xenia Bowlby; his polytechnic course tutor, Alan Slawson, and limited-slip differentials; his car raced in the Clubman (racing car class); he was sponsored by Ripspeed clothing and Spax Performance shock absorbers; Eric Broadly of Lola Cars; he joined Lola Cars in October 1991; he had attempted to gain a place at Lancaster University to study Engineering; Mike Blanchet of Lola Cars; empirical research in designing and building motor racing cars; Mark Williams, head of Formula 3000 at Lola Cars. Narrated by Ian Holm, produced by Michael Proudfoot, directed by Patrick Uden, made by Uden Associates.
“A New Pentacyclic Pyrylium Fluorescent Probe that Responds to pH Imbalance During Apoptosis”. Chem. Sci., 2020,11, 12695-12700. https://doi.org/10.1039/D0SC02623A. A. Mal, S. Vijayakumar, R. K. Mishra, J. Jacob, R. S. Pillai, B. S. Dileep Kumar and Ajayaghosh, Ayyappanpillai (2020). “Supramolecular Surface Charge Regulation in Ionic Covalent Organic Nanosheets for Reversible Exfoliation and Controlled Bacterial Growth”. Angew. Chem., Int. Ed. 2020, 59, 8713-8719. https://doi.org/10.1002/anie.201912363. G, Das.; S, Cherumukkil.; A, Padmakumar.; V, B, Banakar.; V, K, Praveen.; and Ajayaghosh, Ayyappanpillai (2021). “Tweaking a BODIPY Spherical Self-Assembly to 2D Supramolecular Polymers Facilitates Excited State Cascade Energy Transfer”. Angew. Chem. Int. Ed. 2021, 60, 7851-7938. https://doi.org/10.1002/ange.202015390. A, Nirmala.; I, Mukkatt.; S, Shankar.; and Ajayaghosh, Ayyappanpillai (2021). “Thermochromic Color Switching to Temperature Controlled Volatile Memory and Counter Operations with Metal-Organic Complexes and Hybrid Gels”. Angew. Chem., Int. Ed. 2021, 60, 455-465. https://doi.org/10.1002/anie.202011580. I, Mukkatt.; A, P, Mohanachandran.; A, Nirmala.; D, Patra.; P, A, Sukumaran.; R, S, Pillai.; R, B, Rakhi.; S, Shankar.; and Ajayaghosh, Ayyappanpillai (2022). “Tunable Capacitive Behavior in Metallopolymer-based Electrochromic Thin Film Supercapacitors”. ACS Appl. Mater. Interfaces, 2022, 14, 31900-31910. https://doi.org/10.1021/acsami.2c05744
The first attempt to give scientific basis for the cause of this disease was by a ship's surgeon in the Royal Navy, James Lind. While at sea in May 1747, Lind provided some crew members with two oranges and one lemon per day, in addition to normal rations, while others continued on cider, vinegar, sulfuric acid or seawater, along with their normal rations, in one of the world's first controlled experiments. The results showed that citrus fruits prevented the disease. Lind published his work in 1753 in his Treatise on the Scurvy. Fresh fruit was expensive to keep on board, whereas boiling it down to juice allowed easy storage, but destroyed the vitamin (especially if it was boiled in copper kettles). It was 1796 before the British navy adopted lemon juice as standard issue at sea. In 1845, ships in the West Indies were provided with lime juice instead, and in 1860 lime juice was used throughout the Royal Navy, giving rise to the American use of the nickname "limey" for the British. Captain James Cook had previously demonstrated the advantages of carrying "Sour krout" on board by taking his crew on a 1772–75 Pacific Ocean voyage without losing any of his men to scurvy. For his report on his methods the British Royal Society awarded him the Copley Medal in 1776. The name antiscorbutic was used in the eighteenth and nineteenth centuries for foods known to prevent scurvy. These foods included lemons, limes, oranges, sauerkraut, cabbage, malt, and portable soup.
Due to limited data however, more research on potential tolerance and withdrawal effects of moderate doses of doxepin is needed. At these doses of doxepin, dry mouth, an anticholinergic effect, was common (71%), and other side effects such as headache (25%), increased appetite (21%), and dizziness (21%) were also frequently observed, although these adverse effects were notably not significantly more frequent than with placebo in the study in question. In any case, taken together, higher doses of doxepin than very low doses are associated with an increased rate of side effects as well as apparent loss of hypnotic effectiveness with chronic treatment. Doxepin at a dose of 25 mg/day for 3 weeks has been found to decrease cortisol levels by 16% in adults with chronic insomnia and to increase melatonin production by 26% in healthy volunteers. In individuals with neuroendocrine dysregulation in the form of nocturnal melatonin deficiency presumably due to chronic insomnia, very-low-dose doxepin was found to restore melatonin levels to near-normal values after 3 weeks of treatment. These findings suggest that normalization of the hypothalamic–pituitary–adrenal axis and the circadian sleep–wake cycle may be involved in the beneficial effects of doxepin on sleep and insomnia.
The New York Times had also released a video documentary "When A President Says I'll Kill You", which depicts Duterte's war on drugs through a local photographer's eyes. On August 17, 2017, HRW called Duterte a threat to the human rights community after he made threats against human rights activists.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.